EP1472246B1 - Oxadiazoles possedant une activite antiproliferative - Google Patents

Oxadiazoles possedant une activite antiproliferative Download PDF

Info

Publication number
EP1472246B1
EP1472246B1 EP03737409A EP03737409A EP1472246B1 EP 1472246 B1 EP1472246 B1 EP 1472246B1 EP 03737409 A EP03737409 A EP 03737409A EP 03737409 A EP03737409 A EP 03737409A EP 1472246 B1 EP1472246 B1 EP 1472246B1
Authority
EP
European Patent Office
Prior art keywords
compounds
methyl
dihydro
phenyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP03737409A
Other languages
German (de)
English (en)
Other versions
EP1472246A1 (fr
Inventor
Giorgio Cignarella
Gerard Aime Pinna
Gabriele Murineddu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universita degli Studi di Milano
Universita Degli Studi di Sassari
Original Assignee
Universita degli Studi di Milano
Universita Degli Studi di Sassari
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universita degli Studi di Milano, Universita Degli Studi di Sassari filed Critical Universita degli Studi di Milano
Publication of EP1472246A1 publication Critical patent/EP1472246A1/fr
Application granted granted Critical
Publication of EP1472246B1 publication Critical patent/EP1472246B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered

Definitions

  • the present invention relates to oxadiazole derivatives of general formula ( I ) in which:
  • C 1 -C 4 Alkyl is preferably methyl or ethyl.
  • Phenyl-C 1 -C 2 -alkyl is preferably benzyl, optionally substituted on the phenyl ring with one more groups, which can be the same or different, selected from halogen (fluorine, chlorine, bromine, iodine), straight or branched C 1 -C 3 alkyl, C 1 -C 3 alkoxy, trifluoromethyl.
  • C 1 -C 3 Alkoxy is preferably methoxy or ethoxy.
  • the invention also relates to the non toxic salts and solvates of compounds ( I ).
  • R is is hydrogen or methyl
  • R 2 is hydrogen, methyl or optionally substituted substituted phenyl, as defined above.
  • R 2 is phenyl or substituted phenyl, as defined above.
  • Examples of preferred compounds according to the invention comprise:
  • Compounds of formula ( I ) have cytotoxic activity and can be used as antitumor and antiproliferative medicaments.
  • Compounds of formula ( I ) can be prepared by reacting hydrazides of formula ( II ) (scheme 1) wherein X, Y and R are as defined above, with an orthoformate of formula (III) , R 2 C(OEt) 3 (III) in which R 2 has the meaning defined above.
  • the reaction is carried out in a dipolar aprotic solvent, preferably dimethylformamide.
  • step i Compounds of formula ( II ), which are novel and are a further object of the invention, can be obtained as shown in Scheme 2 (step i ), starting from a compound of formula ( IV ), in which X is CH 2 or CH 2 CH 2 and Y is as defined above, by reaction with a cyanoacetic acid ester of formula V CNCH 2 COOR 1 ( V ) in which R 1 has the same meanings as R defined above except for hydrogen, to give the compounds of formula VI , which are then treated with hydrochloric acid gas in ether solution (step ii), to yield the compounds of formula (VII) in which R is hydrogen.
  • the reaction which affords compounds (VI) is also accompanied by formation of compounds (VIII), which are removed with conventional techniques.
  • Step i is preferably carried out in acetone in the presence of potassium bicarbonate, but also other solvents and bases may be used.
  • Compounds ( VII ) can be optionally alkylated at the pyrrole nitrogen (step iii) with an alkylsulfonate of formula ( IX ).
  • the cytotoxic activity of compounds ( I ) was evidenced in primary screening studies on 60 human tumor cell lines. Compounds ( I ) showed marked antiproliferative activity, in particular against leukemias, colon and breast tumors.
  • Compounds of formula ( I ) may therefore be used as antitumor medicaments, more particularly for the treatment of leukemias, colon and breast tumors.
  • compounds of formula ( I ) will be formulated in admixture with suitable excipients and/or carriers according to conventional techniques.
  • the pharmaceutical compositions of the invention may be administered through the oral, parenteral, rectal or topical route.
  • the therapeutical dosages will depend on a number of factors, such as the severity of the disease to treat, the weight, sex and age of the patient as well as the pharmaco-toxicological and pharmacokynetics characteristics of the selected compound of formula ( I ). In principle, the daily dosage will range from 0.01 to 10 mg /kg body weight of the patient.
  • Flash chromatography was performed on silica gel Merck 60 (230-400 mesh ASTM). Thin layer chromatography (TLC) was carried out on plates (0.2 mm) Polygram ® SIL N-HR-/HV 254 .
  • IR spectra were recorded on NaCl pellets (on thin films of the products in Nujol) with a Perkin Elmer 781 IR spectrophotometer and are expressed in ⁇ cm -1 .
  • Compound ( VIIb ) is prepared following the same procedure, but preparing the starting solution with 30 ml of ethyl ether.
  • the resulting residue is taken up into water; the resulting suspension is filtered and the precipitate is washed with ethanol.
  • Compound ( Xb ) is prepared following the same procedure.
  • Compounds (Xc) and (Xd) are purified by extraction of the evaporation residue aqueous solution with ether, evaporation of the ether phase and distillation under low pressure.
  • Table 1 reports the GI 50 , namely the mean concentration ( ⁇ M) of substance which causes a 50% inhibition on the cell growth in preliminary tests carried out on three cell lines (MCF7 breast, NCI-H460 microcitoma and SF-268 SNC).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (9)

  1. Composés de formule générale (I):
    Figure imgb0015
     dans laquelle:
    X est un groupe CH2, CH2CH2 ou CH=CH ;
    R est un atome d'hydrogène, un groupe alkyle en C1-C4 linéaire ou ramifié, ou phényl-(alkyle en C1-C2) ;
    R2 est un atome d'hydrogène, un groupe alkyle en C1-C4 linéaire ou ramifié, ou phényle, éventuellement substitué par un ou plusieurs groupe(s), qui peut(peuvent) être identique(s) ou différent(s), choisi(s) parmi un atome d'halogène (fluor, chlore, brome, iode), un groupe alkyle en C1-C4 linéaire ou ramifié, un groupe alcoxy en C1-C3, un groupe trifluorométhyle ;
    Y est un atome d'hydrogène, un atome d'halogène (fluor, chlore, brome, iode), un groupe alkyle en C1-C4 linéaire ou ramifié, un groupe alcoxy en C1-C3, un groupe trifluorométhyle.
  2. Composés selon la revendication 1, dans lesquels le groupe alkyle en Cl-C4 est le groupe méthyle ou éthyle ; le groupe phényl-(alkyle en C1-C2) est le groupe benzyle, éventuellement substitué sur le cycle phényle par un ou plusieurs groupe(s), qui peut(peuvent) être identique(s) ou différent(s), choisi(s) parmi un atome d'halogène (fluor, chlore, brome, iode), un groupe alkyle en C1-C4 linéaire ou ramifié, un groupe alcoxy en C1-C3, trifluorométhyle ; le groupe alcoxy en C1-C3 est le groupe méthoxy ou éthoxy.
  3. Composés selon les revendications 1 ou 2, dans lesquels X est un groupe CH2 ou CH=CH, R est un atome d'hydrogène ou un groupe méthyle et R2 est un atome d'hydrogène, un groupe méthyle ou un groupe phényle éventuellement substitué, tel que défini selon la revendication 1.
  4. Composé selon la revendication 1, choisi parmi :
    le 3-[[1,3,4]oxadiazol-2'-yl]-1,4-dihydro-indéno[1,2-b]pyrrole ;
    le 3-[[1,3,4]oxadiazole-5'-méthyl-2'-yl]-1,4-dihydro-indéno[1,2-b]pyrrole ;
    le 3-[[1,3,4]oxadiazole-5'-phényl-2'-yl]-1,4-dihydro-indéno[1,2-b]pyrrole ;
    le 1-méthyl-3-[[-[[1,3,4]oxadiazol-2'-yl]-1,4-dihydro-indéno[1,2-b]pyrrole ;
    le 3-[[1,3,4]oxadiazol-2'-yl]-4,5-dihydro-1H-benzo[g]indole ;
    le 3-[[1,3,4]oxadiazole-5'-méthyl-2'-yl]-4,5-dihydro-1H-benzo[g]indole ;
    le 3-[[1,3,4]oxadiazole-5'-phényl-2'-yl]-4,5-dihydro-1H-benzo[g]indole ;
    le 1-méthyl-3-[[1,3,4]oxadiazol-2'-yl]-1H-benzo[g]indole ;
    le 3-[[1,3,4]oxadiazol-2'-yl]-1H-benzo[g]indole;
    le 3-[[1,3,4]oxadiazole-5'-méthyl-2'-yl]-1H-benzo[g]indole;
    le 3-[[1,3,4]oxadiazole-5'-phényl-2'-yl]-1H-benzo[g]indole.
  5. Composé de formule (II)
    Figure imgb0016
     dans laquelle X, Y et R sont tels que définis selon la revendication 1, à l'exclusion du composé dans lequel X est -CH=CH- et Y et R sont l'atome d'hydrogène.
  6. Composés selon la revendication 1 comme médicaments.
  7. Utilisation des composés selon la revendication 1 pour la préparation de médicaments pour la thérapie des tumeurs.
  8. Utilisation selon la revendication 7, dans laquelle les tumeurs sont : les leucémies, les tumeurs du colon, les tumeurs du sein.
  9. Compositions pharmaceutiques contenant les composés selon la revendication 1, en mélange avec des excipients et/ou des supports appropriés.
EP03737409A 2002-02-08 2003-01-31 Oxadiazoles possedant une activite antiproliferative Expired - Lifetime EP1472246B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT2002MI000236A ITMI20020236A1 (it) 2002-02-08 2002-02-08 Ossidazione ad attivita' antiproliferativa
ITMI20020236 2002-02-08
PCT/IB2003/000322 WO2003066628A1 (fr) 2002-02-08 2003-01-31 Oxadiazoles possedant une activite antiproliferative

Publications (2)

Publication Number Publication Date
EP1472246A1 EP1472246A1 (fr) 2004-11-03
EP1472246B1 true EP1472246B1 (fr) 2007-04-04

Family

ID=11449155

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03737409A Expired - Lifetime EP1472246B1 (fr) 2002-02-08 2003-01-31 Oxadiazoles possedant une activite antiproliferative

Country Status (7)

Country Link
US (1) US20070173535A1 (fr)
EP (1) EP1472246B1 (fr)
AT (1) ATE358676T1 (fr)
AU (1) AU2003244513A1 (fr)
DE (1) DE60312959D1 (fr)
IT (1) ITMI20020236A1 (fr)
WO (1) WO2003066628A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102205400B1 (ko) * 2014-02-14 2021-01-21 삼성디스플레이 주식회사 인덴계 화합물 및 이를 포함한 유기 발광 소자

Also Published As

Publication number Publication date
EP1472246A1 (fr) 2004-11-03
WO2003066628A1 (fr) 2003-08-14
DE60312959D1 (de) 2007-05-16
AU2003244513A1 (en) 2003-09-02
ATE358676T1 (de) 2007-04-15
ITMI20020236A0 (it) 2002-02-08
ITMI20020236A1 (it) 2003-08-08
US20070173535A1 (en) 2007-07-26

Similar Documents

Publication Publication Date Title
FI113765B (fi) Menetelmä uusien antiproliferatiivisten 5-substituoitujen kinatsoliiniyhdisteiden valmistamiseksi
Alagarsamy et al. Synthesis and antihypertensive activity of novel 3-benzyl-2-substituted-3H-[1, 2, 4] triazolo [5, 1-b] quinazolin-9-ones
CA3142069A1 (fr) Inhibiteur de la kinase aurora et son utilisation
CZ284023B6 (cs) Ve vodě rozpustné deriváty camptothecinu, způsob výroby a farmaceutické prostředky s jejich obsahem
AU716435B2 (en) Novel indole-2,3-dione-3-oxime derivatives
JPH08503221A (ja) 水溶性カンプトテシン誘導体
EP3992194A1 (fr) Composé de benzodiazépine, son procédé de préparation et son utilisation en médecine
KR870001269B1 (ko) 옥스인돌 카복스 아미드 유도체의 제조방법
CZ299794B6 (cs) Analogy kamptothecinu, zpusob jejich prípravy a farmaceutické prostredky obsahující tyto analogy
PL119501B1 (en) Process for manufacturing novel,condensed pyrimidine derivatives pirimidina
FR2510115A1 (fr) Derives de l'ergoline, procede pour les preparer et leur emploi comme medicament
HU204052B (en) Process for producing imidazopyridazines and pharmaceutical comprising such compounds
SK46793A3 (en) Regenarative melting tank and method of working
HU197011B (en) Process for producing new imidazo- and triazolo-1,4-benzodiazepines and pharmaceuticals comprising the same
SI9300390A (en) Pyrolo :3,2-b: carbazones, 1h benzofuro :3,2-f: indoles and 1h-:1: benzothieno :2,3-f: indoles and their use as anti-tumour agents
EP0172744A2 (fr) Composés de phénazinecarboxamide
WO1996028454A1 (fr) Composes imidazothiazole
Zborovskii et al. Heterocyclization reactions of 2-(2-propynylthio)-4 (1H)-quinazolinone derivatives when treated with electrophilic and nucleophilic reagents
JPH0733743A (ja) ２−アリール−４−キノリノール誘導体
JPH08509740A (ja) カンプトテシンの水溶性誘導体
HU196408B (en) Process for producing tetrahydro-imidazo-quinazolines and stimulators of cardiac action containing them
US20070173535A1 (en) Oxadiazoles having antiproliferative activity
CA2007401A1 (fr) Derives des bisarylalcenes, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
JP4599164B2 (ja) ３位が複素環式基によって置換されたピリドインドロン誘導体、それらの製造法およびそれらの治療用途
WO2015091827A1 (fr) Dérivés de bendamustine et ses composés

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040728

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIN1 Information on inventor provided before grant (corrected)

Inventor name: MURINEDDU, GABRIELE

Inventor name: CIGNARELLA, GIORGIO

Inventor name: PINNA, GERARD AIME

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070404

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070404

Ref country code: CH

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070404

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070404

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REF Corresponds to:

Ref document number: 60312959

Country of ref document: DE

Date of ref document: 20070516

Kind code of ref document: P

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070704

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070715

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070904

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070404

EN Fr: translation not filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070404

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070704

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070404

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070404

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070404

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070404

26N No opposition filed

Effective date: 20080107

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070705

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070705

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070404

Ref country code: FR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20071130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080131

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20080131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070404

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080131

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070404

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070404

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20071005

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070404